Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.49 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 7/20 | 0.46 |
| ▸ | BMPR1A | P36894 | 7/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.46 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506946 | 0.98 | TRIM24 (0.48) | TRIM24ATAD2ALDH1A1GAASMYD3 | |
| SCHEMBL12991998 | 0.85 | ATAD2 (0.41) | TRIM24ATAD2ALDH1A1GAASMYD3 | |
| SCHEMBL736131 | 0.84 | ATAD2 (0.64) | TRIM24ATAD2 | |
| SCHEMBL520474 | 0.81 | ATAD2 (0.53) | ATAD2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL30222138 | 0.79 | TRIM24 (0.54) | TRIM24ALDH1A1GAASMYD3BMPR1B | |
| SCHEMBL434054 | 0.79 | TRIM24 (0.54) | TRIM24ALDH1A1GAASMYD3BMPR1B | |
| SCHEMBL12706597 | 0.79 | RAB9A (0.44) | ATAD2ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5116351 | 0.78 | ATAD2 (0.57) | ATAD2ALDH1A1GAABMPR1BBMPR1A | |
| SCHEMBL1925311 | 0.78 | PKM (0.59) | TRIM24ALDH1A1GAASMYD3BMPR1B | |
| SCHEMBL2643055 | 0.78 | TRIM24 (0.49) | TRIM24ALDH1A1GAASMYD3BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4719391-A2 | TRIPLE KINASE INHIBITORS | Unogen Biotech Ltd. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12435181-B2 | Formulations capable of reacting with or removal of molecular oxygen | LI SHENSHEN (US) | 2025-10-07 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-2134689-A2 | INHIBITORS OF FOCAL ADHESION KINASE | The Scripps Research Institute (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009016119-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016119-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | PFIZER INC | 2008-10-23 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-1781642-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
| WO-2006016221-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | TRIM24 3575/4885ATAD2 4111/4885ALDH1A1 2170/4885 |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | OXA1L, MRPL21, RPS27L | TRIM24 2295/4885ATAD2 1754/4885ALDH1A1 946/4885 |
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | OXA1L, OXSR1, OXER1 | TRIM24 3823/4885ATAD2 1891/4885ALDH1A1 900/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | TRIM24 371/4885ATAD2 1684/4885ALDH1A1 3481/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | TRIM24 371/4885ATAD2 1684/4885ALDH1A1 3481/4885 |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | TRIM24 3093/4885ATAD2 1520/4885ALDH1A1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.